Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mensode is a combination pharmaceutical product developed by Bionova Lifesciences, primarily used as a hematinic for the treatment of iron deficiency anemia. It contains sodium feredetate, a chelated form of iron (sodium iron edetate) that is designed to be more stable and less irritating to the gastrointestinal tract than conventional iron salts. The formulation also includes folic acid (Vitamin B9) and cyanocobalamin (Vitamin B12), which are essential cofactors for DNA synthesis and the maturation of red blood cells. Mensode is typically indicated for patients with anemia due to nutritional deficiencies, pregnancy, or chronic blood loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium feredetate + folic acid + cyanocobalamin.